Pharmacokinetics, Safety, and Antihypertensive Efficacy of Losartan in Combination with Hydrochlorothiazide in Hypertensive Patients with Renal Impairment

The pharmacokinetics and pharmacodynamics of 7 days of treatment with losartan 50 mg/hydrochlorothiazide 12.5 mg were evaluated in 14 patients with normal renal function and in 12 patients with mild to moderate renal impairment. The efficacy of losartan 50 mg/hydrochlorothiazide 12.5 mg titrated to losartan 100 mg/hydrochlorothiazide 25 mg was examined in 32 hypertensive patients with mild to moderate renal impairment who were treated for 12 weeks. Safety was assessed in both studies by the incidence of adverse experiences. After 7 days of treatment, the AUC for losartan, E‐3174, and hydrochlorothiazide was slightly higher in patients with mild to moderate renal impairment, but the reduction in blood pressure (BP) after 7 days was not different between the two groups. The final (week 12) mean reductions in trough sitting diastolic and systolic BP were 15.0 ± 7.1 mmHg (p < 0.01) and 20.8 ± 16.7 mmHg (p < 0.01), respectively. There were no observed increases in drug‐related adverse experiences in either study. Overall, the combination of losartan/hydrochlorothiazide was effective in lowering blood pressure and was well tolerated in patients with mild to moderate renal impairment.

[1]  A. Pinto,et al.  Effect of Long-Term Losartan Administration on Renal Haemodynamics and Function in Hypertensive Patients , 2000, Cardiovascular Drugs and Therapy.

[2]  B. Beermann,et al.  Pharmacokinetics of hydrochlorothiazide in man , 1977, European Journal of Clinical Pharmacology.

[3]  G. Hasenfuss,et al.  Pharmacokinetics of hydrochlorothiazide in relation to renal function , 2004, European Journal of Clinical Pharmacology.

[4]  B. Brenner,et al.  Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion , 2001, Nephron.

[5]  M. Enriquez-Sarano,et al.  Effect of losartan on degree of mitral regurgitation quantified by echocardiography. , 2001, The American journal of cardiology.

[6]  K. Lynn,et al.  A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease. , 2000, Clinical nephrology.

[7]  J. Díez,et al.  Transforming Growth Factor &bgr; in Hypertensives With Cardiorenal Damage , 2000, Hypertension.

[8]  W. Keane,et al.  Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease , 2000, Clinical pharmacokinetics.

[9]  X. Lens,et al.  Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  W. Jiménez,et al.  Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. , 1999, Kidney international.

[11]  F. Maritz,et al.  Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. , 1999, Advances in therapy.

[12]  J. Campistol,et al.  Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. , 1998, Kidney international. Supplement.

[13]  R. Saracho,et al.  Evaluation of the Losartan in Hemodialysis (ELHE) Study. , 1998, Kidney international. Supplement.

[14]  P. Zucchelli,et al.  Comparison of losartan and amlodipine in renally impaired hypertensive patients. , 1998, Kidney international. Supplement.

[15]  A. Hartmann,et al.  Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  J. Edelman,et al.  A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension , 1998, Journal of Human Hypertension.

[17]  M. Macía,et al.  Control of Severe Proteinuria with Losartan after Renal Transplantation , 1998, American Journal of Nephrology.

[18]  P. Ragonesi,et al.  B029: The effects of angiotensin II antagonist losartan on urinary albumin excretion in non insulin-dependent diabetes mellitus , 1998 .

[19]  R. Toto,et al.  Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment , 1998 .

[20]  J. Aguilar,et al.  2.P.108 Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity and lipid profile in hypertensive type II diabetics with microalbuminuria , 1997 .

[21]  J. Chan,et al.  Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. , 1997, American Journal of Nephrology.

[22]  M. Laville,et al.  Effects of losartan on renal function in patients with essential hypertension. , 1996, Journal of cardiovascular pharmacology.

[23]  L. Tomasko,et al.  Absence of a Pharmacokinetic Interaction between Losartan and Hydrochlorothiazide , 1995, Journal of clinical pharmacology.

[24]  T. Bjornsson,et al.  Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans , 1995, Clinical pharmacology and therapeutics.

[25]  B. Wiens,et al.  Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. , 1995, Hypertension.

[26]  W. Keane,et al.  The pharmacokinetics of losartan in renal insufficiency , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[27]  D. de Zeeuw,et al.  Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[28]  F. Guengerich,et al.  Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[29]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[30]  S. Massry,et al.  Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. , 1995, American journal of nephrology.

[31]  B. Matuszewski,et al.  Fully automated methods for the determination of hydrochlorothiazide in human plasma and urine. , 1994, Journal of pharmaceutical and biomedical analysis.

[32]  D. de Zeeuw,et al.  Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[33]  E. Vesell,et al.  Contrasting Effects of Pyrazinoylguanidine and Hydrochlorothiazide in Patients with Renal Insufficiency , 1993, Journal of clinical pharmacology.

[34]  Y. Christen,et al.  Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist , 1992, Clinical pharmacology and therapeutics.

[35]  M. Lo,et al.  Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. , 1992, Journal of chromatography.

[36]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[37]  P. Schollmeyer,et al.  Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension. , 1985, International journal of clinical pharmacology, therapy, and toxicology.

[38]  C T Hung,et al.  Estimation of variance for harmonic mean half-lives. , 1985, Journal of pharmaceutical sciences.

[39]  R. Tarazi,et al.  Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. , 1982, The American journal of medicine.

[40]  N. Bank,et al.  Use of diuretics in treatment of hypertension secondary to renal disease. , 1978, Archives of internal medicine.

[41]  W. Bennett,et al.  Do diuretics have antihypertensive properties independent of natriuresis? , 1977, Clinical pharmacology and therapeutics.

[42]  A. Rosén,et al.  Absorption, metabolism, and excretion of hydrochlorothiazide , 1976, Clinical pharmacology and therapeutics.

[43]  J. Sheldon,et al.  A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. , 1971, The Quarterly journal of medicine.